SCHEMBL110547

SCHEMBL110547

COC(=O)c1cc(Br)nc(-c2ccc(S(=O)(=O)N3CCOCC3)cc2)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
ALDH1A1 P00352 4/20 0.53
GAA P10253 3/20 0.53
HSD17B10 Q99714 2/20 0.53
KDM4E B2RXH2 4/20 0.47
USP2 O75604 1/20 0.47
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 4/20 0.45
RECQL P46063 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 1/20 0.44
HCRTR1 O43613 1/20 0.44
MITF O75030 1/20 0.44
S1PR2 O95136 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL109447 0.85 NPC1 (0.47) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL15976020 0.83 ALDH1A1 (0.45) LMNAALDH1A1GAAHSD17B10KDM4E
SCHEMBL110162 0.82 KMT2A (0.47) ALDH1A1HSD17B10KDM4EMEN1POLB
SCHEMBL110183 0.78 ATR (0.46) ALDH1A1HSD17B10KDM4EMEN1KMT2A
SCHEMBL27998041 0.76 ALDH1A1 (0.55) LMNAALDH1A1GAAHSD17B10KDM4E
SCHEMBL109071 0.76 CA12 (0.42) LMNAALDH1A1GAAHSD17B10KDM4E
SCHEMBL139223 0.76 MAPT (0.47) LMNAALDH1A1GAAHSD17B10KDM4E
SCHEMBL110726 0.76 KMT2A (0.52) ALDH1A1MEN1KMT2AHPGDL3MBTL1
SCHEMBL23958640 0.75 LMNA (0.49) LMNAALDH1A1GAAHSD17B10KDM4E
SCHEMBL110319 0.75 MAPT (0.48) LMNAALDH1A1KDM4EMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 LMNA 4273/4885ALDH1A1 1464/4885GAA 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.